Mayne Pharma launches Lexette foam

BY Sandra Levy

Mayne Pharma is introducing Lexette (halobetasol propionate) foam 0.05%.

The product, which was previously approved by the Food and Drug Administration, is a new formulation of halobetasol, a potent topical corticosteroid indicated for the treatment of plaque psoriasis in adult patients.

Plaque psoriasis affects approximately 7.5 million Americans with potent topical corticosteroids prescribed to approximately 80% of psoriasis patients diagnosed, according to the company.

“Lexette is an elegant foam formulation that will give psoriasis patients more treatment options. The foam delivery platform has a well-established reputation with dermatologists due to ease of application and lack of greasiness and stickiness, especially in hair-bearing areas and under clothing,” Mayne CEO Scott Richards said.


Leave a Reply

No comments found



What area is your company focused most on in 2019?
  • Add your answer